Fair value (multi-method)
Four independent methods triangulate what ABT is worth. The headline is the Forward-DCF intrinsic value at a normalized growth rate; the margin of safety compares it to the current price.
Estimated fair value (Forward DCF)
$96.57
Method range
$96.57 – $170.46
median $122.29
Valuation methods
Each method’s implied fair value per share and its upside versus the current price. Missing methods (no analyst coverage, negative earnings, etc.) are shown as “—”.
| Method | Fair value | Upside vs price |
|---|---|---|
| Forward DCF | $96.57 | -3.98% |
| Exit multiple | $170.46 | +69.50% |
| Analyst target | $122.29 | +21.60% |
| Graham number | — | — |
- Forward DCF$96.57
- Exit multiple$170.46
- Analyst target$122.29
- Graham number—
Stock price
$100.57
EPS (TTM)
$3.11
5Y EPS CAGR
8.3%
Fair value @ hist. growth
$96.57
This analysis is for informational purposes only and is not financial advice. Scenario prices and DCF-style figures depend on your assumptions and data from public filings and estimates. They are not forecasts of future returns.
Implied EPS growth
8.8%
per year over your projection horizon
Margin of safety -4.1% vs hist-growth DCF
Historical 5Y CAGR
8.3%
Your model implies
8.8%
Analyst consensus for next year implies 77.0% — beyond the model's annualised scale. Consensus reflects a one-step EPS estimate vs TTM, not a multi-year CAGR.
Model inputs
Move sliders to test how the reverse DCF reacts. Historical-growth markers show where the company has actually grown over the last cycle.
Sensitivity — implied growth vs your assumptions
Each cell shows the per-share growth rate the market would need to justify the current price at that combination of discount rate (rows) and terminal growth (columns). Your selected inputs are highlighted.
| Row axis: discount rate. Column axis: terminal growth.Terminal g →↓ Discount | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% |
|---|---|---|---|---|---|
| 5.7% | 5.0% | 3.9% | 2.6% | 1.1% | -0.7% |
| 6.7% | 7.9% | 7.0% | 6.0% | 4.8% | 3.5% |
| 7.7% | 10.4% | 9.6% | 8.8% | 7.9% | 6.9% |
| 8.7% | 12.6% | 12.0% | 11.3% | 10.5% | 9.7% |
| 9.7% | 14.8% | 14.2% | 13.6% | 12.9% | 12.2% |
Historical multiples
Each bar is the trailing five-year range (low left, high right). Filled portion runs from low to today; the dot marks today; the small tick marks the five-year median. Low, median, and high are listed under each bar.
Net debt
$6.55B
Total debt − cash
Beta
0.61
Vs market benchmark
Annual diluted EPS
Per-share earnings by fiscal year — last 5 years anchor the CAGR reference above.
Frequently asked questions
Abbott Laboratories (ABT) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
- Buybacks0.44% TTM
- Dividend Profile2.47% yield
- Dividend Calculator
- Dividend Forecast
- Dividend Capture
- Stock Split History9 splits
How this company returns cash to shareholders — buybacks, dividends, and stock splits.